What is Theranostics?

Pluvicto for Metastatic Prostate Cancer

Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) is an outpatient treatment, administered intravenously. It is provided in six cycles of therapy, six weeks apart. Pluvicto concentrates within prostate tumors that express the prostate-specific membrane antigen (PSMA), harming or killing the cancer cells with radiation. Candidates for this therapy must undergo a PSMA PET scan that shows that their tumor(s) concentrate the PET agent, which would be an indication that they would also concentrate the corresponding radiotherapeutic. Pluvicto is well-tolerated, with few side effects, can provide relief from pain and may prolong life.

What Are the Benefits?

• Precise disease detection
• Targeted treatment delivery
• Tailored treatments according to individual patient needs
• Minimizes unnecessary treatments and reduces adverse effects

What to Expect

Your visit to TRA Medical Imaging promises a seamless and exceptional patient experience, reflecting our commitment to your well-being. From the moment you step through our doors, you can expect a warm and welcoming atmosphere where your comfort is our priority. Our compassionate team of healthcare professionals will guide you through every step of your journey, ensuring your questions and concerns are heard and addressed with utmost care.

Pluvicto therapy involves receiving 6 doses intravenously, 6 weeks apart (pending patient health), with diagnostic imaging between treatments. Due to the radioactivity of treatment we encourage patients to drive themselves, if possible. Patients can bring one caregiver; however, the caregiver may not be present during the delivery of the radiopharmaceutical.